


To: **Anjani Womens Day Care Hospital-Bengaluru**
301,9th Main Road,
HRBR Layout 1st Block, Banaswadi
karnataka
Bangalore - 560043
Contact: 9206680471
Report Of: Mrs. DURGAM PRIYADARSHINI
Pt. Contact: 8884908039



Sample ID 2310024476
Patient ID 110237106
Received on 05/06/2023 16:48
Registered on 05/06/2023 19:07
Reported on -
Referred by **DR.KALYANI REDDY**
Sonography by **DR.RAJA A MUNIREDDY**

Understand Your
Report In Detail



Scan QR code

EVICOSCREEN - EVIDENCE BASED COMPREHENSIVE PRENATAL SCREENING REPORT

Patient Name: Mrs. DURGAM PRIYADARSHINI

Patient DOB: 26/08/1992

Sample Type: Serum

Collection Date: 05/06/2023

Method: Electrochemiluminescence (Roche)

EVICScreen™ is an evidence based prenatal screening program curated by Lilac Insights in accordance with the Fetal Medicine Foundation (UK)

guidelines for First Trimester Screening to determine the probability of most common chromosomal aneuploidies in a pregnancy. It utilizes:

- Hormonal values from the pregnancy measured on Fetal Medicine foundation (UK) accredited analyzers and reagents
- Robust indigenous medians from over 7 lac+ pregnancies for different gestation ages
- Risk calculations from evidence based algorithms validated through large international studies

**UKNEQAS: United Kingdom National External Quality
Assessment Service**

**RIQAS: Randox International Quality Assessment
Scheme**



The Risk Assessment Performed Using
CE-Marked Antenatal Risk Evaluation Software
Certified by the British Standards Institute
(BSI)- ISO 13485:2016

| Test Name | Result. | Units |
|------------|---------|-------|
| Free-β-hCG | 23.22 | ng/mL |
| PAPP-A | 4137.00 | mIU/L |

Note

1. Values mentioned above are observed values for PAPP-A & Free β-hCG in the pregnancy on the day of sample collection. These values should not be interpreted in isolation and need to be necessarily incorporated in a validated prenatal Aneuploidy risk calculation software, along with ultrasound and biophysical parameters to calculate the patients individualised risk for aneuploidies like T21, T18, T13 and interpreted accordingly.
2. Biochemical analysis have been performed in accordance to the Fetal Medicine Foundation (FMF) UK guidelines. External QC performed by United Kingdom National External Quality Assessment Service (UKNEQAS). We will appreciate you providing us the outcomes.
3. Divide the values for PAPP-A by 1000 for ASTRAIA Software.



UK NEQAS
International Quality Expertise
Lab Reg. No. 90968

Verified by
Mr. Pradip Kadam
Incharge Biochemistry

Verified by
Dr. Suresh Bhanushali
MD (Path), Consultant Pathologist